{"entity":{"id":"paper-schirripa-kras-g12c-metastatic-colorectal-clin-colorectal-cancer-2020","kind":"paper","name":"KRAS G12C metastatic colorectal cancer: specific features of a new emerging target population","aka":[],"tldr":"As the first KRAS G12C drugs arrived, this study described the patients they would treat: about one in six KRAS-mutant bowel cancers, more often men, more often with lung and liver spread, and with shorter survival than other KRAS mutations.","summary":"Clinicopathological features and outcome data for KRAS-mutant metastatic colorectal cancer patients referred to three Italian oncology units between January 2010 and December 2018 were collected, with a separate Milan cohort as external validation. Of 839 KRAS-mutant patients in the main population, 145 (17%) had a KRAS G12C mutation. G12C patients were more likely to be men and to present with lung and liver metastases, and less likely to have peritoneal spread. KRAS G12C mutation was associated with shorter overall survival than other KRAS mutations (hazard ratio 1.32), a result confirmed in the external validation cohort.","asOf":"2026-09-24","links":[{"label":"Schirripa et al., Clin Colorectal Cancer 2020: KRAS G12C metastatic colorectal cancer in 839 KRAS-mutant patients","url":"https://doi.org/10.1016/j.clcc.2020.04.009"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/32605718/"}],"tags":[],"related":["kras-g12c"],"cancers":["colorectal"],"sections":[],"technologies":["kras-inhibitors"],"targets":["kras"],"drugs":[],"companies":[],"institutions":[],"pathways":["ras-mapk"],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["clinical-colorectal-cancer"],"dependsOn":[],"notes":[],"journal":"Clinical Colorectal Cancer","year":2020,"doi":"10.1016/j.clcc.2020.04.009","pmid":"32605718","authors":"Schirripa M, Nappo F, Cremolini C, et al.","paperType":"observational","findings":["KRAS G12C in 145 of 839 KRAS-mutant patients (17%), about 3% of all colorectal cancers.","More lung and liver metastases, less peritoneal spread.","Shorter overall survival than other KRAS mutations (hazard ratio 1.32)."],"whatItMeans":"It defines the population the G12C inhibitors address and sets the baseline against which CodeBreaK 300 and KRYSTAL-1 are read.","caveats":["Retrospective, from referral centres.","Predates the G12C inhibitors, so the survival figures describe untreated-for-G12C practice."],"changedPractice":false,"participants":839},"route":"/key-papers/paper-schirripa-kras-g12c-metastatic-colorectal-clin-colorectal-cancer-2020/","neighbours":{"biomarker":[{"id":"kras-g12c","kind":"biomarker","name":"KRAS G12C","route":"/biomarkers/kras-g12c/"}],"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"}],"technology":[{"id":"kras-inhibitors","kind":"technology","name":"KRAS & RAS inhibitors","route":"/technologies/kras-inhibitors/"}],"target":[{"id":"kras","kind":"target","name":"KRAS","route":"/targets/kras/"}],"pathway":[{"id":"ras-mapk","kind":"pathway","name":"RAS / RAF / MEK / ERK (MAPK)","route":"/pathways/ras-mapk/"}],"journal":[{"id":"clinical-colorectal-cancer","kind":"journal","name":"Clinical colorectal cancer","route":"/journals/clinical-colorectal-cancer/"}],"drug":[{"id":"adagrasib","kind":"drug","name":"Adagrasib","route":"/drugs/adagrasib/"},{"id":"sotorasib","kind":"drug","name":"Sotorasib","route":"/drugs/sotorasib/"}],"trial":[{"id":"codebreak-300","kind":"trial","name":"CodeBreaK 300","route":"/trials/codebreak-300/"}]}}